Korean biotech specializing in long-acting drug delivery (sustained-release peptide/protein formulations), including Parkinson's and diabetes candidates.
Korean biotech specializing in long-acting drug delivery (sustained-release peptide/protein formulations), including Parkinson's and diabetes candidates.
Moat: narrow (IP / patents). Proprietary long-acting microsphere depot technology applied across licensed drug candidates.
Headquarters: Daejeon, South Korea · Founded: 1997 · Employees: 163
Size Peptron (087010.KS) is a South Korea Health Care company (Biotechnology) with a market value of $1.49B, the 174th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩84,100 on 18 Nov 2026.
Performance Over six months the shares fell 68.4%, against -6.9% for the median peer and -37.2% for the South Korea market (cap-weighted) — lowest of 20 in its peer set.
Growth Revenue fell 12.6% over the last twelve months (peer median +28.0%); the operating margin is -488.1% (peer median -9.6%).
Valuation It trades at 359.6× enterprise value to sales against a peer median of 10.1× (4th most expensive of 18).
Capital Return on invested capital runs 28.1 points below its cost of capital (6.3% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩5.41B | ₩5.63B | ₩3.15B | ₩3.34B | ₩5.81B |
| Revenue growth | — | +79% | -6% | -43% | — |
| Gross profit | -₩964M | ₩760M | -₩1.58B | -₩1.75B | -₩1.47B |
| EBITDA | -₩23.2B | -₩18.5B | -₩13.8B | -₩14.3B | -₩10.7B |
| Net income | -₩27.8B | -₩13.8B | -₩22.0B | -₩15.9B | -₩15.1B |
| Free cash flow | -₩30.9B | -₩23.1B | -₩13.8B | -₩11.7B | -₩13.2B |
| Capital expenditure | ₩15.1B | ₩3.00B | ₩2.16B | ₩869M | ₩1.72B |
| Total debt | ₩31.2B | ₩29.6B | ₩9.24B | ₩9.13B | ₩9.23B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Peptron 087010.KS | $1.49B | -68% | -13% | -488% | 359.6× | n/a |
| HanmiPharm 128940.KS | $3.95B | -2% | +14% | 16% | 3.3× | 4.7% |
| Alkermes Public ALKS | $7.87B | +27% | +15% | 5% | 5.0× | 32.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 087010.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.9% | -10.2% | 6th lowest of 21 |
| 6-month return | -68.4% | -6.9% | lowest of 20 |
| Distance from 52-week high | -78.6% | -44.1% | lowest of 21 |
| Revenue growth (TTM) | -12.6% | +28.0% | 3rd lowest of 18 |
| Operating margin | -488.1% | -9.6% | 5th lowest of 19 |
| EV / Sales | 359.6× | 10.1× | 4th most expensive of 18 |
| ROIC minus cost of capital | -28.1 pp | -9.5 pp | 4th lowest of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | 359.6× | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | 12.8× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.51B | -37% | +12% | 8% | 13.1× | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | n/a | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.52B | +54% | -64% | -5,277% | 1,058.7× | n/a | n/a |
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 6.3× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | 205.0× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.53B | -41% | n/a | n/a | n/a | n/a | n/a |
| Precigen PGEN | United States | $1.53B | 0% | +2,388% | 21% | 10.1× | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.54B | -14% | +739% | 41% | 0.8× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | 2.3× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 4.9× | 39.4% | -2.5% |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | 65.4× | n/a | n/a |
| Vir Biotechnology VIR | United States | $1.57B | +3% | +1,696% | -70% | 4.0× | n/a | n/a |
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | 835.7× | n/a | n/a |
| AnaptysBio ANAB | United States | $1.40B | -22% | +13% | 62% | 7.9× | 0.5% | +25.6% |
| Rapport Therapeutics RAPP | United States | $1.39B | -34% | n/a | -838% | 50.1× | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.61B | +7% | +22% | 7% | 3.4× | n/a | n/a |
| CanSino Biologics 688185.SS | China | $1.38B | 0% | +30% | -4% | 6.6× | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.37B | +181% | +1,749% | -295% | 408.9× | n/a | n/a |